Rituximab-Based Treatment, HCV Replication, and Hepatic Flares

Table 1

Studies on rituximab-based chemotherapy that investigated both HCV reactivation and hepatic flares.

	Coppola et al., 2012 [40]	Ennishi et al., 2010 [36]	Marignani et al., 2011 [39]	Pitini et al., 2010 [38]	Tsutsumi et al., 2009 [37]
Type of study	Observational prospective	Multicentre retrospective	Observational retrospective	Observational prospective	Observational prospective
Disease	LNH, CLL	LNH (DLBCL)	LNH	LNH (DLBCL, FL)	LNH (DLBCL)
Number of cases	8	34	3	10	4
Treatment	R-CHOP in 5	R- and P-based	R-CHOP	RCHOP	R-CHOP in 1
	R-FC in 1	chemotherapy			R-CHO in 2
	CP and then R-FC				R-THP-CO in 1
	in 1
	FC in 1
With HCV reactivation, number of cases:	7	34	2	10	4
During CT	7	34	0	10	4
After CT	0	0	2	0	0
With hepatic flare, number of cases:	7	The available datum (27%) refers to flares observed in 131 patients, of whom only 34 were followed up for HCV RNA	2	10	3
During CT	7		0	10	3
After CT	0		2	0	0

NHL: non-Hodgkin lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; CLL: chronic lymphocytic leukaemia; R-CHO: rituximab, cyclophosphamide, doxorubicin, vincristine; RFC: rituximab, fludarabine, and cyclophosphamide; CP: cyclophosphamide, prednisone; FC: fludarabine and cyclophosphamide; R-THPCOP: rituximab, pirarubicin (tetrahydropyranyl-adriamicin [TPH] ) cyclophosphamid, vincristine without prednisone.